Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Shares Outstanding (Weighted Average): 2023-2025

Historic Shares Outstanding (Weighted Average) for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $138.3 million.

  • Compass Therapeutics' Shares Outstanding (Weighted Average) rose 0.50% to $138.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.3 million, marking a year-over-year increase of 0.50%. This contributed to the annual value of $137.6 million for FY2024, which is 7.92% up from last year.
  • Compass Therapeutics' Shares Outstanding (Weighted Average) amounted to $138.3 million in Q3 2025, which was down 0.00% from $138.3 million recorded in Q2 2025.
  • Compass Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $138.3 million during Q1 2025, with a 5-year trough of $126.5 million in Q1 2023.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $133.9 million, with a median of $137.6 million in 2024.
  • Data for Compass Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY climbed of 8.76% (in 2024) over the last 5 years.
  • Over the past 3 years, Compass Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $127.5 million in 2023, then climbed by 7.92% to $137.6 million in 2024, then grew by 0.50% to $138.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $138.3 million in Q3 2025, compared to $138.3 million in Q2 2025 and $138.3 million in Q1 2025.